Greenlane repays debt, raises capital but revenue collapses 70% and margins vanish

Greenlane Holdings, Inc. (NASDAQ: GNLN)

What's happening inside: management has completed a 1-for-750 reverse stock split (effective June 25, 2025), raised material equity in a February 2025 private placement, paid off all outstanding debt, restructured sales and operations to cut costs, and is executing partnerships to rebuild revenue. The company still faces heavy revenue declines, ongoing net losses, legal risks and internal control remediation work.

Key points & statistics

Cash (June 30, 2025): $5,724 (in thousands)

Total assets: $31,777 (in thousands)

Total liabilities (June 30, 2025): $11,831 (in thousands) - down from $22,349 at 12/31/2024

Working capital (June 30, 2025): ≈ $16.3M (current assets $28,117 less current liabilities $11,826)

Stockholders' equity (June 30, 2025): $19,946 (in thousands) vs $6,282 at 12/31/2024

Income statement highlights (Q2 / YTD)

Net sales - Q2 2025: $788 vs $2,652 (Q2 2024) - down 70%

Net sales - 6 months 2025: $2,257 vs $7,578 (6 months 2024) - down 70%

Gross profit - Q2 2025: $2 vs $1,011 (Q2 2024) - gross margin fell to ~0% from 38%

Gross profit - 6 months 2025: $723 vs $2,523

Loss from operations - Q2 2025: $(3,256) vs $(3,495)

Net loss - Q2 2025: $(3,215) vs $(632)

Net loss - 6 months 2025: $(7,082) vs $(5,123)

Net loss per share - Q2 2025 (basic & diluted): $(3.18) - weighted average shares 1,010,216

Cash flow & financing

Net cash used in operating activities (6 months 2025): $(7,895)

Net cash provided by financing activities (6 months 2025): $12,788 - includes $20,746 proceeds from February 2025 private placement; ~$7,958 paid on notes

Debt: All long-term debt repaid by Feb 2025; debt balance $0 at June 30, 2025

Operational & concentration items

Inventories (June 30, 2025): $14,352

Accounts receivable (net): $3,795

Accounts payable: $8,710

Customer concentration: Two customers ≈ 30% (Q2) and 18% (six months) of net sales - concentration risk

Supplier concentration: Four largest vendors ≈ 38.6% of purchases (Q2 2025)

Governance, compliance & legal

Internal controls: Disclosure controls are not effective; material weaknesses remain and remediation is ongoing.

Nasdaq status: Previously received a delisting notice; later demonstrated bid-price compliance and is under a one-year Discretionary Panel Monitor.

Litigation / investigations: Multiple antitrust purchaser class actions involving Ccell distributions; arbitration demand for unpaid legal invoices; DOJ Civil Investigation Demand re: a subsidiary's PPP loan - potential exposures exist.

Positive aspects of the income statement and financials

1) Improved liquidity position: Cash rose to $5.7M and working capital materially improved versus year-end 2024, driven primarily by the Feb 2025 private placement.

2) Balance sheet repair: Total liabilities materially reduced (major debt extinguished); equity increased to ~$19.9M.

3) Lower interest expense: Interest cost declined after debt repayment, improving future operating leverage potential.

4) Cost cuts visible: Salaries & G&A both declined vs prior year periods, reflecting headcount and other cost reductions.

Negative aspects of the income statement and financials

1) Revenue collapse: Net sales down ~70% YoY for both the quarter and six months - top-line remains the core issue.

2) Gross margin erosion: Q2 gross margin collapsed to ~0% (from 38%) due to slow-moving/damaged inventory write-offs and product mix - undermines recovery prospects.

3) Continued cash burn from operations: $7.9M used in ops in first half of 2025 despite financing inflows - sustainability depends on revenue recovery.

4) Concentration & legal risk: Heavy customer and supplier concentration plus multiple class actions and an investigation increase downside volatility and potential future costs.

5) Control weaknesses: Material weaknesses in internal controls remain - risks to reporting quality and potential remediation costs.

Bottom line: Greenlane raised cash and eliminated its debt, stabilizing the balance sheet. That bought time to execute a restructuring plan and new distribution/marketing partnerships. But revenue is sharply down, margins have collapsed, operating cash burn is significant, and the company faces legal and control risks. The next 12 months hinge on execution: restore sales, protect margins, convert partnerships into revenue, and complete internal-control remediation - otherwise additional financing or strategic alternatives may be required.